Skip to content

CMS-121

Also called CMS121 — a synthetic derivative of the flavonol fisetin from the Salk Institute (Schubert and Maher labs); described in its own literature both as an acetyl-CoA carboxylase 1 (ACC1) inhibitor and as a fatty acid synthase (FASN) inhibitor

A fisetin derivative that acts on the first committed steps of de novo fat synthesis inside the cell.

  • TypeSmall molecule
  • FormOral
  • Researched forCognitive & Mood

Where to get CMS-121

Disguised Alpha
Oral
Code CAMERON

21+ to enter. The only form sold. Research compound, not approved for human use.

Shop oral at Disguised Alpha

The short version

  • Why people research itA geroneuroprotector — a small molecule studied for age-related cognitive decline, brain lipid peroxidation and the metabolic side of aging.
  • What the evidence isThe events more common on drug than placebo were gastrointestinal symptoms and headache.
  • What to watchSevere upper abdominal pain, which can follow very high triglycerides.

How CMS-121 works

This is a flavonol that was taken to a medicinal chemist, and the target it ended up hitting is a fat-synthesis enzyme, not an antioxidant pathway. The starting material was fisetin, an orally active flavonol with neuroprotective and cognition-enhancing activity in animal models.

The mechanism has two published names, and they are one enzyme apart in the same pathway. Currais 2019 reports that CMS121 and its sibling J147 increased the levels of acetyl-CoA in cell culture and in mice via the inhibition of acetyl-CoA carboxylase 1 (ACC1), with neuroprotection and increased acetylation of histone H3K9 in SAMP8 mice, a site the authors link to memory enhancement. One year later Ates 2020 identified fatty acid synthase (FASN) as a molecular target of the same compound.

Its own literature names two adjacent enzymes: the Salk group reported that CMS121 raises acetyl-CoA by inhibiting acetyl-CoA carboxylase 1 (ACC1), the enzyme that carboxylates acetyl-CoA to malonyl-CoA, and separately identified fatty acid synthase (FASN) — the enzyme that condenses malonyl-CoA with acetyl-CoA into palmitate — as a molecular target. Either way the pathway consequence runs the same direction: less newly made fatty acid, and less polyunsaturated substrate available for the iron-dependent lipid peroxidation that drives oxytosis/ferroptosis. Downstream the group reports reduced lipid peroxidation, reduced inflammation and preserved mitochondrial homeostasis, plus increased histone H3K9 acetylation in rapidly aging mice, which is the acetyl-CoA pool showing up as an epigenetic mark. In diabetic and in normally aging mice the same mechanism reads out peripherally as lower triglycerides, lower free fatty acids and a lower liver inflammatory profile.

  • Oral

On the goal map: Hepatic fat & fatty liver (Metabolic health & insulin sensitivity)

Research on CMS-12112 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Evidence on file: Human (Phase 1 complete, 100 healthy volunteers, NCT05318040 — safety, pharmacokinetics and cardiodynamics only; results reported as a medRxiv preprint, not yet peer-reviewed. No efficacy trial has been run in any indication).

Human clinical evidence

  • No deaths and no serious adverse events. The events more common on drug than placebo were gastrointestinal symptoms and headache.

  • Cardiodynamics were measured and were clean. Mean QTcF intervals stayed below 450 msec, changes from baseline stayed below 10 msec, and there were no individual outliers with an absolute QTcF above 450 msec or a change of 30 msec or more. There were no clinically significant laboratory findings.

  • What the phase 1 did not do is test whether it works. It was a safety, tolerability, pharmacokinetics and cardiodynamics study in healthy people. There is no efficacy trial of CMS121 in Alzheimer's disease, in age-related cognitive decline, in metabolic disease or in anything else — not a failed one, a nonexistent one. Note also that the results are currently published as a medRxiv preprint rather than in a peer-reviewed journal, which is a real distinction and not a technicality.

  • The pharmacokinetics carry one finding that matters more than the safety numbers: exposure was higher and the terminal half-life considerably longer in elderly subjects than in young ones, and a high-fat meal raised exposure by about 50%.

Correlative data

  • There is no human observational or association data for CMS121 itself. What exists is a class signal from a different drug, and it points the opposite way to the mouse data: in people with steatohepatitis, pharmacological acetyl-CoA carboxylase inhibition with firsocostat produced hypertriglyceridemia significant enough that a 66-patient trial was run specifically to mitigate it, comparing icosapent ethyl against fenofibrate. Triglycerides rose on the ACC inhibitor and fenofibrate held them roughly flat while icosapent ethyl did not. CMS121 is not firsocostat and its own phase 1 reported no clinically significant laboratory findings over 7 days — but if ACC1 is genuinely the target, triglycerides are the marker to watch and the human direction of travel for the enzyme class is up, not down.

  • The parent compound carries the adjacent literature. Fisetin is an orally active flavonol with published neuroprotective and cognition-enhancing activity in several animal models, and the medicinal chemistry program that produced CMS121 was motivated by fisetin's specific liabilities — a relatively high EC50 in cell assays, low lipophilicity, high topological polar surface area and poor bioavailability. CMS121 was selected from 160 synthetic fisetin derivatives.

  • The ALS record belongs to the parent, not to this molecule. Fisetin itself has been reported to exert antioxidant and neuroprotective effects in multiple mutant hSOD1 models of amyotrophic lateral sclerosis — in Drosophila, in NSC34 cells and in transgenic mice — by activating ERK. A PubTator3 search on 29 September 2026 for CMS121 together with amyotrophic lateral sclerosis returned no study of CMS121 in any ALS model. If you came here for the ALS claim, it is fisetin's.

How the mechanism reads

  • The mechanism has two published names and they are one enzyme apart. The Salk group reported that CMS121 and J147 increased acetyl-CoA levels in cell culture and in mice via inhibition of acetyl-CoA carboxylase 1, producing neuroprotection and increased acetylation of histone H3K9 in SAMP8 mice at a site linked to memory enhancement. A year later the same group identified fatty acid synthase as a molecular target of CMS121 and showed that inhibiting FASN protects against Alzheimer-related toxicities. ACC1 makes malonyl-CoA out of acetyl-CoA; FASN consumes malonyl-CoA and acetyl-CoA to make palmitate. Both are de novo lipogenesis and both predict less newly made fatty acid, but they predict different things about which metabolite piles up, and no published experiment resolves which enzyme is engaged at the exposures a person actually reaches.

    Experimental, animal or cell
  • The cell-death process being targeted is named and it is not apoptosis. Oxytosis/ferroptosis is driven by lipid peroxidation, and the argument for a lipogenesis inhibitor in the brain is substrate control: make less polyunsaturated fatty acid, have less of it to peroxidize. In transgenic AD mice CMS121 reduced cognitive loss while reducing brain lipid peroxidation and inflammation and modulating lipid metabolism.

    Experimental, animal or cell
  • The mouse record is broad and the framing is aging, not one disease. In rapidly aging SAMP8 mice, CMS121 and J147 reduced cognitive decline and metabolic and transcriptional markers of aging while preserving mitochondrial homeostasis; fed only in the last quarter of the lifespan, both compounds improved physiological markers in brain AND kidney, with distinct tissue-specific protein changes in each. In SAMP8 mice treated to 13 weeks of age, CMS121 gave significantly better auditory brainstem response thresholds at 12 and 16 kHz and preserved more inner-hair-cell ribbon synapses.

    Experimental, animal or cell
  • The peripheral metabolic data is the most quantified part of the file. In db/db leptin-receptor-deficient mice fed CMS121 for 6 months: a 5% reduction in body weight, improved glucose tolerance, lower HbA1c and insulin, lower blood and liver triglycerides and free fatty acids, lower liver NF-kappaB, IL-18, caspase 3 and C-reactive protein, and lower urinary NGAL, clusterin and albumin, with renal NDUFB8, UQCRC2 and VDAC restored. In normally aging wild-type mice fed it for 6 months: a 40% decrease in body weight GAIN — gain, not weight — improved glucose and lipid indexes, lower hepatic caspase 1, caspase 3 and NOX4, higher adipose Nrf1, TFAM, GLUT4 and electron-transport markers, a higher resting metabolic rate, and raised plasma short-chain acylcarnitines and butyrate metabolites. The authors describe the profile as mimicking the effects of ketogenic diets.

    Experimental, animal or cell
  • One model result is explicitly partial and the title says so. In R6/2 and YAC128 Huntington's mice, CMS121 slowed motor dysfunction and increased median lifespan, with the YAC128 motor benefit becoming more pronounced as the mice aged, and reduced disease-related changes in proteasome and oxidative-phosphorylation gene expression. The paper is titled *partially* attenuates, which is the correct word and worth keeping.

    Experimental, animal or cell

Sources

CMS-121 safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Severe hypertriglyceridemia or past pancreatitis, because ACC inhibition raises triglycerides.
  • Liver disease or fatty liver with high enzymes, as fat-synthesis blockade acts in hepatocytes.
  • Active cancer, as fatty-acid synthesis inhibition alters tumor metabolism either way.
  • Pregnancy or a young person, given the sparse data on a new lipogenesis inhibitor.

What’s expected

  • Acetyl-CoA rises as de novo fat synthesis is blocked.
  • Mild adverse events in a 100-volunteer study, mostly mild.
  • Cognitive effects are from mouse models, not human trials.

Watch for

  • Severe upper abdominal pain, which can follow very high triglycerides.
  • Yellow eyes with pale stool after starting.
  • Unusual fatigue or tremor.

Labs that tell you it’s working

  • Lipid Panel: triglycerides are the mechanism-predicted shift from ACC1 inhibition.
  • Comprehensive Metabolic Panel: liver enzymes, since fat synthesis is a liver process.
  • Lipase: checked if triglycerides climb and belly pain appears.

Fisetin derivative inhibiting ACC1 (and fatty acid synthase), raising acetyl-CoA; predicted harm is a triglyceride and liver-fat shift. PMID 31742554 PMID 32863221

Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON

CMS-121 FAQ4 common questions

Is CMS-121 approved for human use?
No. CMS-121 is a research compound.
What is CMS-121 researched for?
A geroneuroprotector — a small molecule studied for age-related cognitive decline, brain lipid peroxidation and the metabolic side of aging.
Which labs show whether it's doing anything?
Lipid Panel; Comprehensive Metabolic Panel; Lipase: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for CMS-121: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what CMS-121 is. Skool covers how it is run.

Free on this page

What CMS-121 is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What CMS-121 is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The protocols: what to run together, in what order, for how long and when to stop
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy with codeJoin Skool